NASDAQ losers: Chelsea Therapeutics International (NASDAQ:CHTP), Pharmacyclics (NASDAQ:PCYC), ZIOPHARM Oncology (NASDAQ:ZIOP), Array Biopharma (NASDAQ:ARRY)

Some drugs that have gained approval this year so far include AstraZeneca’s Myalept (complications of leptin deficiency) and Farxiga (type II diabetes), Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) (to treat neurogenic orthostatic hypotension), BioMarin’s Vimizim (Morquio A syndrome) and Vanda Pharma’s Hetlioz. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) stock performance was -5.75% in last session and finished the day at $4.92. Traded volume was 3.02million shares in the last session and the average volume of the stock remained 5.81million shares. The beta of the stock remained 1.82. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) insider ownership is 1.00%.

Pharmacyclics Inc. (NASDAQ:PCYC) and Incyte (INCY) turned in two of the biotech sector’s worst performances, tumbling by 9.6 percent and 9.4 percent, respectively. Pharmacyclics, Inc. (NASDAQ:PCYC) dropped -7.67 percent to $86.11 Friday on volume of 2.70million shares. The intra-day range of the stock was $83.85 to $92.84. Pharmacyclics, Inc. (NASDAQ:PCYC) has a market capitalization of $6.46billion.

ANI Pharmaceuticals and ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) sport a Zacks Rank #1 (Strong Buy). ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)’s stock on Apr 11, 2014 reported a decrease of -6.74% to the closing price of $3.60. Its fifty two weeks range is $1.55-$5.58. The total market capitalization recorded $362.00million. The overall volume in the last trading session was 2.60million shares. In its share capital, ZIOP has 100.56million outstanding shares.

Array Biopharma Inc (NASDAQ:ARRY), reported at the 2014 American Academy of Allergy, Asthma & Immunology or AAAAI, Annual Meeting, the full results of Phase 2 trials for its product ARRY-502, which is an oral CRth2 antagonist. On Friday, shares of Array Biopharma Inc (NASDAQ:ARRY) dropped -7.93% to close the day at $3.83. Company return on investment (ROI) is -65.80% and its monthly performance is recorded as -24.75%. Array Biopharma Inc (NASDAQ:ARRY) quarterly revenue growth is -27.87%.